Powdered insulin to prevent type-1 diabetes in children
A new clinical trial will investigate if giving powdered insulin to babies at high risk of developing type-1 diabetes can be a solution to prevent the disease.BBC News
Conclusions: The reactivity to VEGF inhibitors varied among different subtypes of nAMD. The efficacy of intravitreal anti-VEGF therapy in type 3 nAMD was statistically better than type 1 when considering vision improvement at 3 and 12 months. Thus, the lesion subtype is a predictor for the treatment outcome which can help guide prognosis. PMID: 30425852 [PubMed]
Jane E. Yardley, Nicole K. Brockman, Richard M. Bracken
Publication date: Available online 14 November 2018Source: Life SciencesAuthor(s): Simone Marcieli Sartoretto, Fernanda Fernandes Santos, Beatriz Pereira Costa, Graziela Scalianti Ceravolo, Rosângela Santos-Eichler, Maria Helena Catelli Carvalho, Zuleica Bruno Fortes, Eliana Hiromi AkamineAbstractAimsInflammation is involved in diabetes-related vascular dysfunction. Estrogen receptor ESR2/ERβ induces the expression of inducible nitric oxide (NO) synthase (iNOS) and inflammation. The present study investigated the effect of alloxan-induced type 1 diabetes on the iNOS and ESR2 expression and the effect of the chro...
AbstractBackgroundTransforming growth factor- β1 (TGF-β1) is a multifunctional cytokine that has numerous biological processes. Earlier research indicates that protein and mRNA production of TGF-β1 are enhanced in the renal tissues of patients with diabetic nephropathy (DN). Our aim was to evaluate the role of TGF-β1 in early prediction of DN in children with type 1 diabetes mellitus (T1DM).MethodsFifty patients with T1DM were enrolled in an observational study. Patients were eligible to participate if at least 3 years had passed since T1DM diagnosis. Patients were classified into two groups (A and B) a...
Condition: Type 1 Diabetes Mellitus Interventions: Drug: LY900014; Drug: Insulin Lispro Sponsor: Eli Lilly and Company Not yet recruiting
Technology that allows parents of kids with type 1 diabetes to remotely monitor their children's glucose levels improves parents'psychosocial outcomes.Medscape Medical News
Publication date: Available online 13 November 2018Source: Artificial Intelligence in MedicineAuthor(s): Nicola Falcionelli, Paolo Sernani, Albert Brugués, Dagmawi Neway Mekuria, Davide Calvaresi, Michael Schumacher, Aldo Franco Dragoni, Stefano BromuriAbstractPersonal Health Systems (PHS) are mobile solutions tailored to monitoring patients affected by chronic non communicable diseases. In general, a patient affected by a chronic disease can generate large amounts of events: for example, in Type 1 Diabetic patients generate several glucose events per day, ranging from at least 6 events per day (under normal monitor...
CONCLUSIONS: Nanoencapsulated probucol-ursodeoxycholic acid resulted in significant levels of insulin in the blood, lower levels of secondary bile acids in liver and lower levels of primary bile acids in brain, while ratio of secondary to primary bile acids remains similar among all groups, except in the faeces. Findings suggests that nanoencapsulated probucol-ursodeoxycholic acid may exert a protective effect on pancreatic β-cells and reserve systemic insulin load via modulation of bile acid concentrations in the liver and brain. PMID: 30422681 [PubMed - as supplied by publisher]